Drugs / DISITERTIDE
DISITERTIDE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00781053 | Jul 2008 → Dec 2010 | cutaneous sclerosis | ISDIN | Completed | No outcome recorded |
| Phase 2 | NCT00574613 | Sep 2007 → Nov 2009 | cutaneous sclerosis | ISDIN | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00656825 Comparator | Mar → Jun 2007 | — | ISDIN | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DISITERTIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108346 ↗ |
| Known as | Disitertida | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108346 ↗ |
| Known as | P144 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00574613 ↗ |
| Known as | Peptide 144 | “Peptide 144 (P144)is a acetic salt of a 14mer peptide from human TGF-beta1 type III receptor (betaglycan).” NCT00781053 ↗2“Peptide 144 (P144) is the acetic salt of a 14mer peptide from human TGF-β1 type III receptor (betaglycan).” NCT00574613 ↗ “Peptide 144 (P144) is the acetic salt of a 14mer peptide from human TGF-β1 type III receptor (betaglycan).” NCT00656825 ↗ |
| Known as | Peptide 144 tgf beta-1-inhibitor | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108346 ↗ |
| Action | Inhibit | “P144 TGF-β1-inhibitor has been specifically designed to block the interaction between TGF-β1 and TGF-β1 type III receptor” NCT00574613 ↗ |
| Modality | Peptide | “Peptide 144 (P144) is the acetic salt of a 14mer peptide” NCT00574613 ↗ |
| Route | Topical | “topical application of P144” NCT00574613 ↗ |
| Target | TGFB1 | “P144 TGF-beta1-inhibitor has been specifically designed to block the interaction between TGF-beta1 and TGF-beta1 type III receptor” NCT00781053 ↗ |